Staurosporine

Staurosporine is a potent, ATP-competitive and non-selective inhibitor of protein kinases with IC50s of 6 nM, 15 nM, 2 nM, and 3 nM for PKC, PKA, c-Fgr, and Phosphorylase kinase respectively. Staurosporine also inhibits TAOK2 with an IC50 of 3 μM. Staurosporine is an apoptosis inducer[1][2][3][4][5].

Product Specifications

CAS Number

[62996-74-1]

Product Name Alternative

Antibiotic AM-2282; STS; AM-2282

UNSPSC

12352005

Hazard Statement

H361, H413

Target

Antibiotic; Apoptosis; Bacterial; Fungal; PKA; PKC

Type

Natural Products

Related Pathways

Anti-infection; Apoptosis; Epigenetics; Stem Cell/Wnt; TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/Staurosporine.html

Purity

99.98

Solubility

DMSO : 62.5 mg/mL (ultrasonic)

Smiles

O=C(NC1)C2=C1C3=C(C4=C2C5=C(C=CC=C5)N4[C@H]6C[C@@H](NC)[C@@H](OC)[C@]7(C)O6)N7C8=CC=CC=C83

Molecular Formula

C28H26N4O3

Molecular Weight

466.53

Precautions

H361, H413

References & Citations

[1]Meggio F, et al. Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. Eur J Biochem. 1995 Nov 15;234 (1) :317-22.|[2]Chae HJ, et al. Molecular mechanism of staurosporine-induced apoptosis in osteoblasts. Pharmacol Res. 2000 Oct;42 (4) :373-81.|[3]Yoshizawa S, et al. Tumor-promoting activity of staurosporine, a protein kinase inhibitor on mouse skin.Cancer Res. 1990 Aug 15;50 (16) :4974-8.|[4]Nabeshima T, et al. Staurosporine facilitates recovery from the basal forebrain-lesion-induced impairment of learning and deficit of cholinergic neuron in rats. J Pharmacol Exp Ther. 1991 May;257 (2) :562-6.|[5]Yujie Ren, et al. The ORF3a Protein of SARS-CoV-2 Induces Apoptosis in Cells. Cell Mol Immunol. 2020 Jun 18;1-3.